- (2025): Kozarac S+, Blood Rev Jan, Online ahead of print [REVIEW]
Adverse reactions attributed to entire drug class 'Bruton's tyrosine kinase (BTK) inhibitor'
Please login to view adverse reactions.
- (2024): Zhang Y+, Cancers (Basel) 16(5), 8605–20% (grade 3–grade 5) [REVIEW]
- (2024): Zhang Y+, Cancers (Basel) 16(5), 8600–19% (grade 3–grade 5) [REVIEW]
Leukocytopenia (leukopenia) / leukocytes (white blood cells) decreased
- (2024): Zhang Y+, Cancers (Basel) 16(5), 8602–20% (grade 3–grade 5) [REVIEW]
Lymphopenia (lymphocytopenia) / lymphocytes decreased
- (2024): Zhang Y+, Cancers (Basel) 16(5), 8600–56% (grade 3–grade 5) [REVIEW]
Neutropenia (neutrophils decreased)
- (2024): Zhang Y+, Cancers (Basel) 16(5), 8604–22% (grade 3–grade 5) [REVIEW]
- (2023): Tao Y+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 44(6), 490-49412%
Thrombocytopenia / platelets decreased
- (2024): Zhang Y+, Cancers (Basel) 16(5), 8602–18% (grade 3–grade 5) [REVIEW]
- (2023): Tao Y+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 44(6), 490-49410%
Adverse effects / adverse reactions
- (2024): Song Z+, Chin J Cancer Res 36(3), 240-256 [REVIEW]
- (2023): Ghane Y+, Heliyon 9(12), e22912 [REVIEW]
- (2022): Arustamyan M+, Eur J Haematol Aug, Online ahead of print [REVIEW]
- (2022): Wan Q+, Front Pharmacol Nov (e-Collection) (associations)
